Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Repligen Corporation - Common Stock (NQ:RGEN)

131.06 -1.04 (-0.79%)
Streaming Delayed Price Updated: 10:10 AM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Repligen Corporation - Common Stock

< Previous 1 2 3 4 5 6 Next >
Repligen (RGEN): Buy, Sell, or Hold Post Q4 Earnings?
Repligen trades at $120.32 per share and has moved almost in lockstep with the market over the last six months. The stock has lost 10.5% while the S&P 500 is down 7.7%. This might have investors... 
Via StockStory
Topics Stocks
Exposures US Equities
Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how IQVIA (NYSE:IQV) and the rest... 
Via StockStory
Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Medpace (NASDAQ:MEDP) and its peers. 
Via StockStory
Demystifying Repligen: Insights From 6 Analyst Reviews
Via Benzinga
The Analyst Verdict: Repligen In The Eyes Of 4 Experts
Via Benzinga
Earnings Scheduled For February 20, 2025
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
Evaluating Repligen: Insights From 6 Financial Analysts
Via Benzinga
Q4 Rundown: PacBio (NASDAQ:PACB) Vs Other Life Sciences Tools & Services Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at PacBio (NASDAQ:PACB) and its peers. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Q4 Earnings Recap: Azenta (NASDAQ:AZTA) Tops Drug Development Inputs & Services Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Azenta (NASDAQ:AZTA) and its peers. 
Via StockStory
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including Repligen (NASDAQ:RGEN) and... 
Via StockStory
3 Small-Cap Stocks Skating on Thin Ice
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
These Analysts Revise Their Forecasts On Repligen Following Q2 Results
Via Benzinga
908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth
Repligen acquires 908 Devices' desktop portfolio for $70 million, enhancing its bioprocessing analytics. 908 Devices shifts focus to handheld growth, forecasting revenue gains. 
Via Benzinga
Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook
Repligen reported Q4 EPS of $0.44, beating estimates, with revenue of $167.55 million. The company projects 2025 sales of up to $710 million as the market recovers. 
Via Benzinga
Repligen's Q4 Slightly Tops Expectations
The bioprocessing technology specialist's fourth-quarter results were dragged down by restructuring costs. 
Via The Motley Fool
Repligen (NASDAQ:RGEN) Posts Q4 Sales In Line With Estimates
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) met Wall Street’s revenue expectations in Q4 CY2024, but sales were flat year on year at $167.5 million. The company’s outlook for the... 
Via StockStory
Exposures COVID-19
Earnings To Watch: Repligen (RGEN) Reports Q4 Results Tomorrow
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be announcing earnings results tomorrow morning. Here’s what you need to know. 
Via StockStory
3 Healthcare Stocks Skating on Thin Ice
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But near-term speed bumps have persisted in the wake of COVID-19 as players destocked inventories in 2023 and... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Repligen Q3 Earnings Beat Expectations, Highlights Improving Market Conditions, Analyst Says Well-Positioned For Long-Term Growth
Repligen Q3 earnings beat expectations with $0.43 EPS and $154.87 million in sales. The company raises 2024 EPS guidance and reports strong growth in CDMO and equipment. 
Via Benzinga
Topics Earnings
Exposures Financial
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Wall Street Ticks Up As Consumer Sentiment Improves; Gold Hits Record Highs, Boosting Mining Stocks: What's Driving Markets Friday?
Wall Street edged slightly higher on Friday, with major equity indices showing modest gains at midday in New York. 
Via Benzinga
Shake Shack And Lumen Tech Are Among Top 7 Mid Cap Stocks With Max Gains Last Week (July 28-August 3): Are The Others In Your Portfolio?
Seven mid-cap stocks that performed well last week: LUMN, SHAK, PSN, CWAN, RGEN, FTDR, and NEO. Check if they're in your portfolio! 
Via Benzinga
Here's Why Shares in This Hot Healthcare Stock Surged This Week
The bioprocessing market is preparing for a recovery. 
Via The Motley Fool
Repligen Lowers Guidance On China Weakness, Analyst Expects
Repligen reports Q2 sales of $154.1 million, closely matching the consensus estimate. Adjusted gross margin fell to 49.6% from 50.2%, with an EPS of $0.33. CEO Tony J. Hunt highlights strong Pharma... 
Via Benzinga
PayPal Posts Upbeat Earnings, Joins Sprouts Farmers Market, Stanley Black & Decker, Phillips 66 And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
This Robinhood Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Via Benzinga
NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Top 3 Health Care Stocks That Could Blast Off In June
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.